FDA Reverses Course, Will Review Moderna’s mRNA Flu Vaccine
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA has reversed its previous stance and will review Moderna's mRNA flu vaccine. This decision is a change from the agency's earlier position, although the specifics of the initial decision and the reasoning behind the reversal are not clear. The FDA will now move forward with reviewing Moderna's flu vaccine application.
Full coverage
1
NPR·Feb 182
CIDRAP·Feb 183
CNBC·Feb 184
The Guardian·Feb 185
CNN·Feb 186
STAT·Feb 187
Reuters·Feb 188
The New York Times·Feb 18